Transport of nanomedicines across the blood-brain barrier: Challenges and opportunities for imaging and therapy
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
The blood-brain barrier (BBB) is a protective and semipermeable border of endothelial cells that prevents toxins and foreign bodies to enter and damage the brain. Unfortunately, the BBB also hampers the development of pharmaceuticals targeting receptors, enzymes, or other proteins that lie beyond this barrier. Especially large molecules, such as monoclonal antibodies (mAbs) or nanoparticles, are prevented to enter the brain. The limited passage of these molecules partly explains why nanomedicines - targeting brain diseases - have not made it into the clinic to a great extent. As nanomedicines can target a wide range of targets including protein isoforms and oligomers or potentially deliver cytotoxic drugs safely to their targets, a pathway to smuggle nanomedicines into the brain would allow to treat brain diseases that are currently considered 'undruggable'. In this review, strategies to transport nanomedicines over the BBB will be discussed. Their challenges and opportunities will be highlighted with respect to their use for molecular imaging or therapies. Several strategies have been explored for this thus far. For example, carrier-mediated and receptor-mediated transcytosis (RMT), techniques to disrupt the BBB, nasal drug delivery or administering nanomedicines directly into the brain have been explored. RMT has been the most widely and successfully explored strategy. Recent work on the use of focused ultrasound based BBB opening has shown great promise. For example, successful delivery of mAbs into the brain has been achieved, even in a clinical setting. As nanomedicines bear the potential to treat incurable brain diseases, drug delivery technologies that can deliver nanomedicines into the brain will play an essential role for future treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Feigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., Culpepper, W. J., Dorsey, E. R., Elbaz, A., Ellenbogen, R. G., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30499-x · Cited by 5,644
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
Transvascular delivery of small interfering RNA to the central nervous system
Kumar, P., Wu, H., McBride, J. L., Jung, K.-E., Hee Kim, M., Davidson, B. L., Kyung Lee, S., Shankar, P., & Manjunath, N. (2007) · Nature · doi:10.1038/nature05901 · Cited by 1,246
Intranasal delivery to the central nervous system: Mechanisms and experimental considerations
Dhuria, S. V., Hanson, L. R., & Frey, W. H. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21924 · Cited by 1,239
Pardridge, W. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.013 · Cited by 1,191
Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions
William Rebeck, G., Reiter, J. S., Strickland, D. K., & Hyman, B. T. (1993) · Neuron · doi:10.1016/0896-6273(93)90070-8 · Cited by 1,107
Transferrin receptor on endothelium of brain capillaries
Jefferies, W. A., Brandon, M. R., Hunt, S. V., Williams, A. F., Gatter, K. C., & Mason, D. Y. (1984) · Nature · doi:10.1038/312162a0 · Cited by 1,061
Current Strategies for Brain Drug Delivery
Dong, X. (2018) · Theranostics · doi:10.7150/thno.21254 · Cited by 954
Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors
Uchida, Y., Ohtsuki, S., Katsukura, Y., Ikeda, C., Suzuki, T., Kamiie, J., & Terasaki, T. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07208.x · Cited by 881
Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J. M., Prabhu, S., Watts, R. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002230 · Cited by 794
Transport of drugs across the blood–brain barrier by nanoparticles.
Wohlfart, S., Gelperina, S., & Kreuter, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.017 · Cited by 715
Characteristics of Compounds that Cross the Blood-Brain Barrier
Banks, W. A. (2009) · BMC Neurology · doi:10.1186/1471-2377-9-s1-s3 · Cited by 710
Luissint, A.-C., Artus, C., Glacial, F., Ganeshamoorthy, K., & Couraud, P.-O. (2012) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-9-23 · Cited by 654
Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier
Lockman, P. R., Mumper, R. J., Khan, M. A., & Allen, D. D. (2002) · Drug Development and Industrial Pharmacy · doi:10.1081/ddc-120001481 · Cited by 592
Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation
Jones, A. R., & Shusta, E. V. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9379-0 · Cited by 549
CSF, blood-brain barrier, and brain drug delivery
Pardridge, W. M. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1171315 · Cited by 508
Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges
Pulgar, V. M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01019 · Cited by 482
Osmotic Opening of the Blood–Brain Barrier: Principles, Mechanism, and Therapeutic Applications
Rapoport, S. I. (2000) · Cellular and Molecular Neurobiology · doi:10.1023/a:1007049806660 · Cited by 428
Progress in brain targeting drug delivery system by nasal route
Khan, A. R., Liu, M., Khan, M. W., & Zhai, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.001 · Cited by 402
Targeting Receptor-Mediated Transport for Delivery of Biologics Across the Blood-Brain Barrier
Lajoie, J. M., & Shusta, E. V. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124852 · Cited by 399
Ronaldson, P. T., & Davis, T. P. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20951995 · Cited by 392
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
Yu, Y. J., Atwal, J. K., Zhang, Y., Tong, R. K., Wildsmith, K. R., Tan, C., Bien-Ly, N., Hersom, M., Maloney, J. A., Meilandt, W. J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009835 · Cited by 371
PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up
Operti, M. C., Bernhardt, A., Grimm, S., Engel, A., Figdor, C. G., & Tagit, O. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120807 · Cited by 302
Hoshi, Y., Uchida, Y., Tachikawa, M., Inoue, T., Ohtsuki, S., & Terasaki, T. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23575 · Cited by 254
Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor
Hultqvist, G., Syvänen, S., Fang, X. T., Lannfelt, L., & Sehlin, D. (2017) · Theranostics · doi:10.7150/thno.17155 · Cited by 224
Viral disruption of the blood–brain barrier
Spindler, K. R., & Hsu, T.-H. (2012) · Trends in Microbiology · doi:10.1016/j.tim.2012.03.009 · Cited by 219
Ullman, J. C., Arguello, A., Getz, J. A., Bhalla, A., Mahon, C. S., Wang, J., Giese, T., Bedard, C., Kim, D. J., Blumenfeld, J. R., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1163 · Cited by 205
Theranostic USPIO‐Loaded Microbubbles for Mediating and Monitoring Blood‐Brain Barrier Permeation
Lammers, T., Koczera, P., Fokong, S., Gremse, F., Ehling, J., Vogt, M., Pich, A., Storm, G., van Zandvoort, M., & Kiessling, F. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201401199 · Cited by 156
Pardridge, W. M. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.952627 · Cited by 152
Delivery of Biologics Across the Blood–Brain Barrier with Molecular Trojan Horse Technology
Pardridge, W. M. (2017) · BioDrugs · doi:10.1007/s40259-017-0248-z · Cited by 152
Tashima, T. (2020) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c19-00854 · Cited by 120
Targeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases
Anthony, D. P., Hegde, M., Shetty, S. S., Rafic, T., Mutalik, S., & Rao, B. S. S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119326 · Cited by 110
Exploiting transferrin receptor for delivering drugs across the blood-brain barrier
Paterson, J., & Webster, C. I. (2016) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2016.07.009 · Cited by 87
Prabhu, S., Goda, J. S., Mutalik, S., Mohanty, B. S., Chaudhari, P., Rai, S., Udupa, N., & Rao, B. S. S. (2017) · Nanoscale · doi:10.1039/c7nr00305f · Cited by 54
Fu, C., Xiang, Y., Li, X., & Fu, A. (2018) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.12.029 · Cited by 48
Samiotaki, G., Karakatsani, M. E., Buch, A., Papadopoulos, S., Wu, S. Y., Jambawalikar, S., & Konofagou, E. E. (2017) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2016.11.023 · Cited by 35
Cited by
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906
“In brief, the molecules can partition into the cellular membranes from the top to the bottom lateral side through carrier-mediated and receptor-mediated transcytosis.(154) In particular, lipophilic carriers and some other known carrier systems like cationic amino acids are mainly transported via the transcellular path…”
BackgroundClinical translation of nanomedicines for brain diseases: Current challenges and future directions
Wang, G., Wang, N., Xia, X., Ismail, M., & Shi, B. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114426 · Cited by 33
Pramoda, G., Verma, R. K., Kesharwani, P., & Shukla, R. (2025) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2025.127938 · Cited by 15
Metadata
- Authors
- van den Broek, S. L., Shalgunov, V., & Herth, M. M.
- Venue
- Biomaterials Advances
- Publisher
- Elsevier BV
- Published
- 2022-10
- Volume
- 141
- Pages
- 213125
- ISSN
- 2772-9508 (ISSN-L)
- OpenAlex
- W4296311472
- Cited by
- 52
- References
- 38
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.